James William Burns - 02 Apr 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Apr 2026, 16:11:49 UTC
Prior SEC filing
03 Mar 2026
Next SEC filing
23 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ William Cook, as Attorney in Fact for James Burns

Key filing fact

James William Burns filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 06 Apr 2026.

Key facts

  • This page summarizes James William Burns's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 06 Apr 2026, 16:11.

Change

  • Previous filing in this sequence was filed on 03 Mar 2026.
  • Current net transaction value: -$113,849.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001900772 Primary reporting owner

Burns James William

Relationship
Chief Legal Officer
Address
88 SIDNEY STREET, CAMBRIDGE
Signature
/s/ William Cook, as Attorney in Fact for James Burns
Signature date
06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGIO transaction

Common stock

Options Exercise

Transaction value
Shares
+8,500
Change %
+19%
Price
$0.000000*
Shares after
52,586
Date
02 Apr 2026
Ownership
Direct
AGIO transaction

Common stock

Sale

Transaction value
$113,849
Shares
-3,280
Change %
-6.2%
Price
$34.71
Shares after
49,306
Date
02 Apr 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Performance share units

Options Exercise

Transaction value
Shares
-8,500
Change %
-50%
Price
$0.000000*
Shares after
8,500
Date
02 Apr 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
8,500
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024.

Footnote F2

Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F3

The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .